BeiGene Welcomes Experienced Life Sciences Executive Olivier Brandicourt to Board of Directors
23 Enero 2024 - 5:00AM
Business Wire
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global
biotechnology company, today announced that Olivier Brandicourt,
M.D. has been appointed to its Board of Directors. Dr. Brandicourt
will join the audit committee of the Board.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240123611725/en/
Olivier Brandicourt, M.D. (Photo:
Business Wire)
Dr. Brandicourt replaces Thomas Malley, who has served on the
Board since 2016.
“Dr. Brandicourt brings a wealth of global experience as we
expand the perspective of BeiGene’s Board of Directors to include
deep expertise in leading multinational growth companies,
spearheading launches in a range of therapeutic areas and scaling
into new geographies,” said John V. Oyler, Chairman, CEO and
Co-Founder at BeiGene. “The Board looks forward to working with Dr.
Brandicourt, who drove excellence as an outstanding leader for
multiple global pharmaceutical brands, as we continue our evolution
as a next-generation oncology innovator. Tom has been an invaluable
member of the board with service dating back before the Company’s
IPO. We thank him for his dedicated service and incredible
contributions to BeiGene’s global success and wish him well.”
“I am pleased to join BeiGene’s Board and help advance the
Company’s mission to bring innovative cancer medicines to more
patients around the world,” said Dr. Brandicourt. “Through my
decades of pharmaceuticals and medical leadership, I have committed
my career to ensuring equitable global access to improve patient
outcomes. It is an honor to serve alongside my fellow Board members
who share my commitment to this goal.”
About Olivier Brandicourt
Olivier Brandicourt is a prominent executive in the
pharmaceuticals industry with decades of management, medical and
marketing experience. He is currently a Senior Advisor at
Blackstone Life Sciences and a director of Alnylam Pharmaceuticals,
Inc., BenevolentAI S.A., and Dewpoint Therapeutics, Inc. He also
serves as chair of the board of AvenCell Therapeutics, Inc.
Prior to joining Blackstone Life Sciences, Dr. Brandicourt
served as CEO and as a member of the board of directors of Sanofi
S.A. from 2015 to 2019. Dr. Brandicourt was the CEO and chair of
Bayer HealthCare AG from 2013 to 2015. From 2000 to 2013, Dr.
Brandicourt held a series of leadership positions at Pfizer Inc.,
including as President and General Manager of Global Specialty
Care, Global Primary Care and most recently of the Emerging Markets
and Established Products business units. Dr. Brandicourt was part
of the Pfizer Executive team from 2010 to 2013.
Dr. Brandicourt studied medicine in Paris, where he specialized
in Infectious Diseases and Tropical Medicine, and holds a master’s
degree in biology from Paris XII University and an advanced degree
in cellular and immunological pathophysiology from the Paris
Descartes University.
During his tenure at Sanofi, Dr. Brandicourt was elected
Chairman of the Board of Management of the Pharmaceutical Research
and Manufacturers of America and Vice President of the European
Federation of Pharmaceutical Industries and Associations. He is an
Honorary Fellow of the Royal College of Physicians in London.
The full Board of Directors list is available on the BeiGene
website at
https://www.beigene.com/our-company-and-people/leadership-and-board/#CorporateLeaders.
About BeiGene
BeiGene is a global biotechnology company that is discovering
and developing innovative oncology treatments that are more
affordable and accessible to cancer patients worldwide. With a
broad portfolio, we are expediting development of our diverse
pipeline of novel therapeutics through our internal capabilities
and collaborations. We are committed to radically improving access
to medicines for far more patients who need them. Our growing
global team of more than 10,000 colleagues spans five continents,
with administrative offices in Basel, Beijing, and Cambridge, U.S.
To learn more about BeiGene, please visit www.beigene.com and
follow us on LinkedIn and X (formerly known as Twitter).
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
and other federal securities laws, including statements regarding
the expected contributions of the new board member and BeiGene’s
plans, commitments, aspirations, and goals under the heading “About
BeiGene.” Actual results may differ materially from those indicated
in the forward-looking statements as a result of various important
factors, including BeiGene's ability to demonstrate the efficacy
and safety of its drug candidates; the clinical results for its
drug candidates, which may not support further development or
marketing approval; actions of regulatory agencies, which may
affect the initiation, timing and progress of clinical trials and
marketing approval; BeiGene's ability to achieve commercial success
for its marketed medicines and drug candidates, if approved;
BeiGene's ability to obtain and maintain protection of intellectual
property for its medicines and technology; BeiGene's reliance on
third parties to conduct drug development, manufacturing,
commercialization, and other services; BeiGene’s limited experience
in obtaining regulatory approvals and commercializing
pharmaceutical products and its ability to obtain additional
funding for operations and to complete the development of its drug
candidates and achieve and maintain profitability; and those risks
more fully discussed in the section entitled “Risk Factors” in
BeiGene’s most recent quarterly report on Form 10-Q as well as
discussions of potential risks, uncertainties, and other important
factors in BeiGene's subsequent filings with the U.S. Securities
and Exchange Commission. All information in this press release is
as of the date of this press release, and BeiGene undertakes no
duty to update such information unless required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240123611725/en/
Investor Contact Liza Heapes +1 857-302-5663
ir@beigene.com
Media Contact Kyle Blankenship +1 667-351-5176
media@beigene.com
BeiGene (NASDAQ:BGNE)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
BeiGene (NASDAQ:BGNE)
Gráfica de Acción Histórica
De May 2023 a May 2024